Vor Biopharma Inc. (VOR) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Vor Biopharma reported revenue of $0. Net income was -$696.0M, or -$70.50 per diluted share. Operating activities generated -$142.7M of cash, leaving -$143.7M of free cash flow. At fiscal year end, Vor Biopharma held $464.1M in total assets against $628.4M in total liabilities, including $396.5M of cash and equivalents.
Open the full interactive Vor Biopharma financials → Quarterly statements, key ratios, valuation history and price charts.
Vor Biopharma Key Stats
| Share Price | $19.06 |
|---|---|
| Market Cap | $1.04B |
| 52-Week Range | $6.86 – $32.29 |
| Shares Outstanding | 54.3 million (basic, 2026 Q2) |
Vor Biopharma Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$69.0M | -$93.4M | -$126.0M | -$121.2M | -$371.6M |
| Pre-Tax Income | -$68.9M | -$92.1M | -$117.9M | -$116.9M | -$696.0M |
| Net Income | -$68.9M | -$92.1M | -$117.9M | -$116.9M | -$696.0M |
| Diluted EPS | -$42.00 | -$46.60 | -$35.00 | -$34.00 | -$70.50 |
Vor Biopharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$812.7M | $1.72B | -$219.6M | -$62.8M |
| Diluted EPS | -$121.63 | $174.52 | -$5.11 | -$1.16 |
Vor Biopharma Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $119.8M | $57.7M | $31.4M | $81.9M | $396.5M |
| Current Assets | $214.4M | $236.9M | $140.8M | $96.5M | $458.1M |
| Total Assets | $242.6M | $299.4M | $198.1M | $142.9M | $464.1M |
| Current Liabilities | $10.2M | $13.1M | $15.6M | $18.6M | $25.2M |
| Total Liabilities | $26.3M | $48.8M | $47.4M | $46.2M | $628.4M |
| Shareholders' Equity | $216.3M | $250.6M | $150.7M | $96.7M | -$164.3M |
Vor Biopharma Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$69.1M | -$85.1M | -$100.3M | -$99.7M | -$142.7M |
| Cash From Investing | -$91.7M | -$94.1M | $71.0M | $96.9M | -$48.8M |
| Cash From Financing | $232.9M | $117.1M | $2.9M | $53.4M | $503.8M |
| Free Cash Flow | -$73.0M | -$93.6M | -$101.4M | -$99.9M | -$143.7M |
Figures from Vor Biopharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Vor Biopharma financials page for every line item.
Vor Biopharma Company Profile
| Ticker | VOR |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Boston, Massachusetts |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001817229 |
Frequently Asked Questions
What was Vor Biopharma's revenue in fiscal 2025?
Vor Biopharma (VOR) reported revenue of $0 for fiscal 2025.
What is Vor Biopharma's annual revenue history?
Vor Biopharma's annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Vor Biopharma's net income in fiscal 2025?
Vor Biopharma reported net income of -$696.0M for fiscal 2025.
What was Vor Biopharma's earnings per share (EPS) in fiscal 2025?
Vor Biopharma's diluted EPS was -$70.50 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Vor Biopharma generate in fiscal 2025?
Vor Biopharma generated -$143.7M of free cash flow in fiscal 2025.
What was Vor Biopharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), Vor Biopharma reported revenue of $0.
How many shares of Vor Biopharma are outstanding?
Vor Biopharma reported a weighted average of 54.3 million basic shares outstanding in 2026 Q2.
What is Vor Biopharma's market cap?
Based on its latest closing price, Vor Biopharma (VOR) has a market capitalization of about $1.04B.
When does Vor Biopharma's fiscal year end?
Vor Biopharma's fiscal year end, as registered with the SEC, is December 31.
Where is Vor Biopharma headquartered?
Vor Biopharma lists its business address in Boston, Massachusetts in its SEC filings.
Vor Biopharma Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →